RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Zai Lab of Shanghai has dosed the first patient in a China Phase III registration trial of ZL-2306 (niraparib) as a first-line maintenance therapy for platinum-responsive ovarian cancer. Niraparib is an oral, once-daily PARP 1/2 inhibitor that Zai believes could be a first-in-class Category 1 drug in China for treating multiple solid tumor types. Zai also expects to begin a Phase III trial of niraparib for small cell lung cancer by mid-2018.
Source: China Biotoday